In bid to avoid immunotherapy toxicities, Cartography charts a course toward modality-agnostic drugs
In the early days of the Covid-19 pandemic, Kevin Parker was wrapping up his PhD work on regenerative medicine and stem cell biology at Stanford. By the end of 2020, he was setting up a new biotech to squash toxicity issues with immunotherapies by charting an atlas of antigens that might point to more precise targets.
Parker and his co-founders — Stanford professors Howard Chang and Ansu Satpathy, a faculty fellow at Carolyn Bertozzi’s ChEM-H institute — secured seed financing in 2020 from Andreessen Horowitz and have now lined up a $57 million Series A, marking the unveiling of the Foster City, CA-based biotech. Parker tells Endpoints News the Series A was raised at the end of 2021 and will likely bring the startup toward the clinic, with a Series B needed to translate preclinical work into human studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
